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Multidrug-resistant tuberculosis treatment
failure detection depends on monitoring
interval and microbiological method
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ABSTRACT Debate persists about monitoring method (culture or smear) and interval (monthly or less
frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing data
and estimated the effect of monitoring strategies on timing of failure detection.
We identified studies reporting microbiological response to MDR-TB treatment and solicited individual
patient data from authors. Frailty survival models were used to estimate pooled relative risk of failure
detection in the last 12 months of treatment; hazard of failure using monthly culture was the reference.
Data were obtained for 5410 patients across 12 observational studies. During the last 12 months of
treatment, failure detection occurred in a median of 3 months by monthly culture; failure detection was
delayed by 2, 7, and 9 months relying on bimonthly culture, monthly smear and bimonthly smear,
respectively. Risk (95% CI) of failure detection delay resulting from monthly smear relative to culture is
0.38 (0.34–0.42) for all patients and 0.33 (0.25–0.42) for HIV-co-infected patients.
Failure detection is delayed by reducing the sensitivity and frequency of the monitoring method.
Monthly monitoring of sputum cultures from patients receiving MDR-TB treatment is recommended.
Expanded laboratory capacity is needed for high-quality culture, and for smear microscopy and rapid
molecular tests.
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Introduction
In 2013, 20% of the 480000 multidrug-resistant tuberculosis (MDR-TB) cases estimated among notified
pulmonary TB cases received appropriate second-line treatment [1]. Myriad challenges hamper attempts
to provide universal access to MDR-TB treatment: lengthy, toxic treatment; inadequate supply of
high-quality drugs; limited human resources; complex adverse event management; and a dearth of
laboratory resources to diagnose MDR-TB and monitor treatment response [2]. Early in MDR-TB
treatment, monthly culture and smear monitoring of treatment response are recommended; more frequent
monitoring is recommended for patients with HIV disease and other comorbidities [3]. After sputum
culture conversion [4], which occurs ∼3 months after treatment initiation [5], recommendations are for
less frequent culture with monthly smear examination. Historically, this has meant at least quarterly
culture with monthly smear for the last 12 months of an 18–24-month regimen [3].
Costs of the different monitoring methods are variable and overlapping, ranging from $1.63 to $62.01 for
culture and $0.26 to $10.50 for smear [6]. Key to selection of frequency and method of monitoring is
information on their performance characteristics. A recent meta-analysis found that both smear and
culture have low sensitivity and modest specificity for predicting relapse in drug-susceptible TB [7].
Additional reports establish a relationship between earlier culture conversion and successful treatment
outcome [8, 9], and detection of initial conversion and reversion is delayed with less frequent monitoring
during MDR-TB treatment [9].
The present report investigates the effect of monitoring interval (monthly versus bimonthly or quarterly)
and method (smear versus culture) on timing of treatment failure detection during the final 12 months of
treatment delivered under routine programme conditions. Preliminary results of this investigation, which
used an individual patient-data meta-analysis, informed the 2011 update of the World Health Organization
(WHO) Guidelines for the Programmatic Management of Drug-resistant Tuberculosis [10, 11] and are
updated and published here in their entirety.
Methods
Study selection
The present study extends the work of the Collaborative Group for Meta-analysis of Individual Patient
Data in MDR-TB [12–14]. Articles eligible for the present analysis were included in either of two
published meta-analyses of MDR-TB treatment [15, 16] and in AHUJA et al.’s [12] 2012 meta-analysis of
individual patient data. Additional sources were identified by WHO guidelines committee members.
E-mail correspondence was used to request datasets, data dictionaries, definitions and clarification; in
some cases, individual patient data on more or different patients from those included in the original
analysis were provided. Summary information was used to assess initial eligibility. Exclusion criteria were
duplicate datasets; nonprimary research; language other than English, French or Spanish; data comprising
only extensively drug-resistant TB patient populations; and no response after three or more requests to
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participate. Included studies used second-line drugs in reported treatment; had a sample size >25 patients;
and had monthly culture data.
Compilation of the parent dataset has been described previously [12, 13, 17]. The study was exempted
from review by Harvard Medical School’s committee on human subjects research. Data-use agreements
executed with all participating projects stipulated that those who provide data will seek approval or
exemption from local institutional review boards as appropriate.
Analysis
The following were evaluated among all patients in the included studies: 1) does timing of failure detection
during the final 12 months of treatment differ across monitoring frequencies and methods? and 2) is this
difference modified by patient characteristics?
All analyses were performed using Stata 12 (StataCorp, College Station, TX, USA).
The end-point was time to detection of bacteriological failure, classified as two or more positive cultures (or
smears) in the last 12 months of treatment (failure month was the month of the second positive result) or at
least one positive culture (or smear) in the last 3 months of treatment (failure month was the month of the
first positive result), according to the consensus definitions in place when most primary data were collected
[18]. For one included study [19], in which a large proportion of patients received a 9-month treatment
regimen, failure was defined as a single positive culture among the last three cultures. Data handling
conventions favoured failure: if multiple results were available in a single month, any positive result was
used. In addition, missing observations were imputed by carrying the last value forward. Lastly, when there
were missing observations among the last three expected observations, the analysis retrieved prior
observations until there were three. All increased the probability of including positive cultures (or smears),
and detecting failure. Consequently, failure percentages may be higher than those previously reported.
We simulated three monitoring scenarios against which we compared the timing of “observed failure” or
failure detected by monthly culture in the final 12 months: one using only monthly smear; the second
using results from samples collected every other month (to simulate bi-monthly monitoring) and the third
using results from samples collected every third month (to simulate quarterly monitoring). We estimated
the timing of 1) failure detected by monthly smear only (primary analysis); 2) failure detected by
bimonthly culture or smear; and 3) failure detected by quarterly culture or smear and compared each to
the timing of observed failure. For each culture result, any positive smear within 14 days (either side) was
elected as the corresponding smear result.
Unweighted pooled frequencies were calculated for descriptive statistics. Monthly concordance between
smear and culture results during the whole treatment was estimated by calculating the mean proportion
(with 95% confidence intervals) of concordant intra-patient results in each month.
Kaplan–Meier estimates of failure time in the last 12 months were calculated using standard techniques.
Heterogeneity was evaluated using I2. To evaluate the validity of pooled results in the presence of
heterogeneity, we performed an additional analysis that included intercepts and interaction terms for each
cohort, allowing us to obtain 12 realisations of the heterogeneous outcome (and corresponding error
estimates). We then generated 1000 hypothetical sets of 12 realisations of the outcome, and calculated the
mean and standard error for each of the 1000 sets. By estimating the means of these two statistics we
obtained an estimate of the heterogeneity of the outcome across different cohorts. Alternative monitoring
strategies were compared to monthly culture using frailty survival models (random intercept) to estimate
the relative hazard of failure, pooled over all sites. Effect estimates were also calculated separately for each
study site. Reported hazard ratios reflect the risk of failure detection: a hazard ratio of <1 indicates delayed
detection, while a hazard ratio of >1 indicates earlier detection. We assessed heterogeneity in patient
characteristics through stratification by study site, HIV serostatus, baseline smear result, radiography
findings, low body mass index (<18.5 kg·m−2). Multivariable (i.e. adjusted) regressions were considered
and rejected as high rates of missing data resulted in unstable complete case analyses. We performed
sensitivity analysis of the time to failure detection excluding patients with missing baseline bacteriology.
Results
Study selection and population
Search strategy and results are presented in figure 1. Review of the meta-analyses yielded 30 possible
datasets. 21 additional potential data sources were identified by the guidelines committee and through
reference lists. Five more were identified through the US Centers for Disease Control and Prevention
(CDC)-sponsored case-based data collection efforts. Out of 56 summaries/abstracts evaluated for eligibility,
nine were excluded. The remaining datasets and full articles were reviewed; 12 were eligible for inclusion
and 35 were excluded for the following reasons: four studies did not use second-line drugs; one study
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reported on fewer than 25 patients; nine authors did not respond to requests for data; and smear and
culture data were missing or insufficient in 21 studies (figure 1). In total, 12 datasets with 5730 unique
patient treatment records were included; seven were from six separate published articles and five from the
case-based data collection coordinated by the CDC, previously described [5, 9]. Table 1 illustrates the
distribution of 12 study sites across 11 countries. Of note, four studies were conducted in Eastern Europe.
At least one on-treatment culture result was available for 5410 (94.4%) patients with confirmed MDR-TB.
In just over 20%, baseline smear (1117) and culture (1119) status was unrecorded, but subsequent
monitoring data were available. These 5410 patients were included in analyses.
Approximately one-third (33.5%) of patients were female. Mean age ranged from 31.1 to 48.0 years
(pooled estimate 37.0 years). The availability of data on and distribution of cavitary, bilateral disease
varied. Among those with drug-susceptibility test results for the five first-line drugs, most had isolates
resistant to four or five (91%). Second-line drug susceptibility test results were available in only 43.7% of
observations and are not reported here. Data on HIV serostatus, body mass index and chest radiography
findings were missing in 37.2%, 59.0% and 40.0% of observations, respectively (table 2).
Treatment outcomes, calculated according to consensus definitions [17] varied across studies: cure frequencies
ranged from 16.3% at site 6 to 74.1% at site 12. Failure was observed in 16.9% (914) of cases (table 3).
Concordance of monthly smear and culture results
We evaluated the intra-observation agreement of smear and culture during the first 24 months of
treatment, stratified by treatment outcome (died, cured/completed or failed). Summary results are
presented in table 3 and figure 2. As smear and culture conversion occurred, concordance increased.
Uncertainty around the estimates increased later in follow-up as fewer patients remained on treatment and
contributed observations (online supplementary material). Mean agreement across months was greatest for
those who were cured by or completed treatment (95.6%, 95% CI 85.7–100.0%). The type of discordance
varied: among deaths and failures, smear-negative/culture-positive pairs were more common. Among
cures, smear-positive/culture-negative pairs were more common. However, the latter occurred roughly as
frequently among cures as among deaths and failures.
Studies identified from AHUJA et al. [12], 
JOHNSTON et al. [16] and ORENSTEIN et al.'s [15]  
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FIGURE 1 Search strategy and results. MDR-TB: multidrug-resistant tuberculosis; CDC: US Centers for
Disease Control and Prevention; XDR-TB: extensively drug-resistant tuberculosis.
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Timing of failure detection by monitoring strategy
The timing of failure detection in the last 12 months of treatment varied within and across the monitoring
strategies (figure 3). In the last 12 months of treatment monthly culture detected the first positive result
that contributed to the failure definition in a median (interquartile range (IQR)) 3 (0.8–7.0) months; by
bimonthly culture and quarterly culture, median detection occurred in 5 (2.0–10.0) months and 6 (2.0–
12.0) months, respectively. Failure was detected by monthly smear in 10 (2.0–12.0) months. The rate of
failure detection is lower for monthly smear relative to monthly culture (HR (95% CI) 0.38 (0.34–0.42))
and for quarterly culture compared to monthly culture (0.58 (0.53–0.64)).
Stratified analysis of failure detection in the last 12 months comparing monthly smear to monthly culture
revealed further variability. First, detection was delayed by using smear alone at seven sites (1, 3, 6, 8–10
and 12), while no significant change in risk could be discerned elsewhere (figure 4a). The rate of failure
detection by exclusive monthly smear monitoring was lower in patients with baseline negative sputum
smears (HR (95% CI) 0.17 (0.13–0.23)) than in patients with baseline positive smears (0.46 (0.41–0.53)).
No difference was observed in failure detection by HIV status; in both HIV-negative and HIV-positive
patients, monthly smear delayed failure detection compared to monthly culture (HIV− 0.42 (0.36–0.50),
HIV+ 0.33 (0.25–0.42); figure 4b).
There was significant heterogeneity (I2 83.5%, p<0.001) in the pooled analyses of the difference between
smear and culture. Nevertheless, the sensitivity analysis that was stratified by site produced results similar
to those observed in the survival frailty model. Excluding patients with missing baseline smear and culture
results did not change the effect estimates. The high proportion of missing data for several covariates
resulted in small numbers in complete case analyses; these are not presented.
Discussion
This study combined individual patient data from multiple sources to investigate differences in time to
failure detection in the last 12 months of MDR-TB treatment resulting from reducing the frequency or
changing the method of bacteriological monitoring. Failure was detected most promptly with monthly
culture. At any given time point during the 12-month evaluation period, quarterly culture was half as
likely as monthly culture (and monthly smear was only 38% as likely as monthly culture) to detect failure.
Earlier detection of treatment nonresponse may enhance the ability to adjust treatment regimens to avert
poor outcomes, decrease the probability of death and reduce transmission due to uncontrolled disease
[11]. The present results do not support changing the frequency or method of monitoring in the last
TABLE 1 Summary of studies included





1 BURGOS [20] San Francisco, CA,
USA
72 Individualised
2 COX [21] Uzbekistan 77 2003–2005 Individualised
3 HOLTZ [22] South Africa 2211 2000–2004 Mixed standardised
and individualised
4 MIGLIORI [23] Estonia 321 2006–2008# Individualised
5 MIGLIORI [23] Italy 71 2003–2006 Individualised
6 SHEAN [24] South Africa 345 1990–1999§ Individualised




Estonia 274 2001–2005 Individualised
9 Latvia (CDC-sponsored
case-based data collection)
Latvia 449 2000–2001 Individualised
10 Lima, Peru+ (CDC-sponsored
case-based data collection)
Lima, Peru 742 1997–2002 Individualised
11 Philippines (CDC-sponsored
case-based data collection)
Manila, Philippines 170 1999–2003 Individualised
12 Tomsk, Russia+ (CDC-sponsored
case-based data collection)
Tomsk, Russia 244 2000–2002 Individualised
CDC: US Centers for Disease Control and Prevention. #: inclusion of MIGLIORI et al. [23] (Estonia) restricted to 2006–2008 to avoid overlap with
CDC-sponsored case-based data collection from Estonia [7]; §: inclusion of SHEAN et al. [24] data restricted to 1990–1999 to avoid overlap with
Holtz et al. [22]; +: Partners In Health/Socios En Salud.
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TABLE 2 Characteristics of the study population (all subjects with some in-treatment culture data)
Site/dataset Site location (and dates
when >1 cohort/location)















1 San Francisco, CA, USA 55 45.3 (53) 45.7 (53) 15.2 (46) 0 19 21.1 73.7
2 Uzbekistan 77 39.0 (77) 36.8 (77) 0.0 (77) 71.4 (77) 77 28.6 27.4 77 32.5 67.5
3 South Africa (2000–2004) 2092 37.7 (2089) 36.5 (2070) 64.4 (1326) 59.8 (455) 1425 14.6 80.9 0
4 Estonia (2006–2008) 274 27.7 (274) 48.0 (274) 4.1 (268) 30 20.0 36.7 274 10.2 89.1
5 Italy 71 39.4 (71) 37.8 (71) 7.2 (69) 70 24.3 44.3 71 16.9 71.9
6 South Africa (1990–1999) 319 37.3 (319) 33.9 (251) 4.6 (109) 158 48.1 39.2 51 23.5 3.9
7 Bangladesh 668 28.0 (668) 34.2 (668) 83.7 (325) 0 653 28.8 56.4
8 Estonia (2001–2005) 292 28.1 (292) 44.3 (292) 3.4 (262) 18.6 (161) 282 57.1 16.3 0
9 Latvia 446 22.6 (446) 42.4 (446) 3.3 (360) 20.4 (437) 442 52.0 21.9 446 22.9 75.1
10 Lima, Peru 712 40.3 (712) 31.1 (712) 1.3 (631) 28.4 (437) 579 43.7 31.1 437 18.1 78.3
11 Manila, Philippines 161 36.0 (161) 39.6 (161) 0.0 (9) 42.0 (81) 31 0.0 0.0 150 22.0 67.3
12 Tomsk, Russia 243 13.6 (243) 34.4 (243) 0.0 (242) 19.3 (243) 135 45.9 21.5 191 36.6 62.3
Pooled frequency 5410 33.5 (5405) 37.0 (5318) 26.8 (3399) 41.7 (2216) 3229 32.1 51.5 2369 23.3 68.7
Data are presented as % (n) or %, unless otherwise stated. BMI: body mass index; HR: isoniazid–rifampicin. #: refers to the number of patients in each cohort, with some culture






















12 months of treatment. These main results helped to inform the WHO 2011 revised treatment guidelines
for the programmatic management of MDR-TB [10].
These findings highlight the particular value of performing at-least monthly cultures throughout treatment
among subgroups. In particular, in patients with smear-negative TB at baseline, culture was even more
critical to detecting failure during the final 12 months, since positive cultures often were detected before
positive smears. Although not surprising, these findings lend evidence to programmatic decision-making
for this subgroup. HIV-infected patients are another subgroup in whom these results suggest continued
use of monthly culture monitoring. Although there was no effect modification on delay of failure detection
by HIV serostatus, sputum-smear microscopy is known to have significantly decreased sensitivity in
HIV-co-infected TB patients [25–27]. In addition, delays in appropriate treatment can have more serious
consequences in HIV-positive patients than among HIV-negative patients [28, 29]. Therefore, it would be
reasonable to employ monitoring strategies that can detect and permit intervention in at-risk patients at
the earliest possible juncture. This reaffirms previous recommendations to monitor these patients more
aggressively throughout treatment [3].
Additional benefits of early failure detection must be considered in evaluation of monitoring costs. In
absolute terms, work by LU et al. [6] estimated that culture costs between 1.4 and 12.0 times more than
smear, with significant variability. Monthly culture would increase these differences by three-fold
compared to quarterly culture. However, patients affected by MDR-TB are often in the most productive























































FIGURE 2 Intra-observation agreement of smear and culture during the first 24 months of treatment,
stratified by treatment outcome.
TABLE 3 Outcome distribution across reports
Site/dataset Site location (and dates
when >1 cohort/location)
Subjects n Cure/completion Failure Death Default/transfer
1 San Francisco, CA, USA 55 67.3 (37) 12.7 (7) 9.1 (5) 10.9 (6)
2 Uzbekistan 77 66.2 (51) 13.0 (10) 13.0 (10) 7.8 (6)
3 South Africa (2000–2004) 2092 37.2 (778) 23.7 (496) 16.9 (354) 22.2 (464)
4 Estonia (2006–2008) 274 54.0 (148) 12.0 (33) 14.6 (40) 19.3 (53)
5 Italy 71 45.1 (32) 36.6 (26) 12.7 (9) 5.6 (4)
6 South Africa (1990–1999) 319 16.3 (52) 23.8 (76) 37.6 (120) 22.3 (71)
7 Bangladesh 668 84.3 (563) 5.5 (37) 4.8 (32) 5.4 (36)
8 Estonia (2001–2005) 292 45.2 (132) 19.5 (57) 13.0 (38) 22.3 (65)
9 Latvia 446 63.9 (285) 16.4 (73) 4.5 (20) 15.2 (68)
10 Lima, Peru 712 65.6 (467) 8.0 (57) 17.1 (122) 9.3 (66)
11 Manila, Philippines 161 60.9 (98) 11.2 (18) 11.2 (18) 16.8 (27)
12 Tomsk, Russia 243 74.1 (180) 9.9 (24) 4.5 (11) 11.5 (28)
Pooled frequency 5410 52.2 (2823) 16.9 (914) 14.4 (779) 16.5 (894)
Data are presented as % (n), unless otherwise stated. Cure/completion and failure were calculated retrospectively using all available culture
data per consensus definitions; default, transfer and death were programme-assigned.
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additional monitoring should be evaluated in the context of the societal benefits of avoiding bad outcomes:
mortality, acquisition of additional resistance and the creation of new cases of MDR-TB through
transmission [30–36]. Future work could examine the relative impact and costs associated with different
screening approaches, including in a dynamic model that addresses potential transmission. Such work
could further estimate the individual and population impacts of monitoring policies, and associated costs
and resource demands.
These findings raise the question of when and how to intervene to avert a predicted negative outcome.
Guidelines recommend repeat drug susceptibility testing among patients whose cultures have not converted
or have reverted after month 4. Although the present study demonstrates that failure can be predicted
earlier with more frequent culture supplementing smear testing, additional clinical evaluation is required to
determine which patients with positive culture results at month 4 or later require treatment adjustment to
assure success and which will experience successful treatment outcome without any regimen adjustments.
FIGURE 3 The timing of failure
detection in the last 12 months of
treatment within and across the
monitoring strategies. Data are
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FIGURE 4 Stratified analysis of failure detection in the last 12 months of treatment, comparing monthly smear to monthly culture. Panel a)
presents individual (by study) and pooled hazard ratios (95% confidence intervals). Panel b) presents hazard ratios (95% confidence intervals)
stratified by risk factors. BMI: body mass index. HR: isoniazid–rifampicin.
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Benefits of reinforcing regimens with at least two new drugs, or considering adjunct interventions (e.g.
surgery) [37], could accrue to patients receiving both individualised and standardised regimens [3].
These findings highlight the importance of further developing laboratory capacity for proper management
of MDR-TB. Although dissemination of rapid tests for diagnosis of rifampicin-resistant TB has accelerated
in recent years, this has not been accompanied by scaled-up culture services. Current minimum
recommendations for improving diagnosis of smear-negative TB advise that high-burden countries have at
least one culture laboratory per 5 million population. This low bar has been met in only 21 countries.
Scaled-up culture capacity, to permit both regular monitoring throughout MDR-TB treatment and
confirmatory drug susceptibility testing after molecular tests, is desperately needed to advance the goals of
TB pre-elimination and elimination [35, 38, 39].
Limitations
There are several limitations to this study. First, large numbers of missing values for covariates precluded
assessment of confounding; complete case analysis would have included only 78 of the 914 patients who
failed. Second, there was substantial heterogeneity. However, stratified analyses revealed similar conclusions
to the pooled analyses. Third, generalisability may be limited, as all sites included used the most frequent
and sensitive monitoring method (monthly culture), which suggests a relatively strong health system.
Fourth, this analysis was performed using the previous consensus definitions for treatment outcomes. The
new definitions are still largely microbiologically based [40], so the general conclusions should not differ
substantially with the new definitions. Last, variability in laboratory methods and quality, and in
treatment, may have introduced unmeasured bias. Most sources of potential bias would result in
underestimating the effect of substituting less sensitive monitoring for monthly culture. The one exception
is smear quality, which was not directly assessed. If smear quality was suboptimal, the difference between
smear and culture could be overestimated. At site 7, which invested substantially in smear quality, the
estimated risk of detecting failure by smear versus culture was not statistically distinguishable from the
null, highlighting this potential bias. However, all study sites participated in routine internal quality
control and external quality assurance, so there is no reason to suspect poor quality of sputum smears.
Conversely, the effect of substituting smear for culture may be underestimated. This is because only a
small, unspecified proportion of the cultures were grown in liquid media, which is more sensitive than
solid culture [41]. Since routine use of liquid culture is increasing, the true delay in failure detection
incurred by substituting smear results for liquid culture results will probably be greater. Also creating the
potential for bias toward the null is the use of individualised treatment in all sites except site
7. Individualised regimens are more likely than standardised regimens to be adjusted based on early
indication of nonresponse. Although the simulated datasets do not use all available data, in practice,
clinicians may have used results that were not counted in one of the less-frequent monitoring scenarios, to
recommend a treatment change or adjunctive therapy, thereby averting failure. Consequently, the effect of
less-sensitive monitoring on failure of individualised treatment may be underestimated.
Conclusions
Reduced frequency of culture monitoring or replacement of culture by sputum smear even in the final
12 months of treatment could threaten early detection of failure. Compromise on method could lead to
greater delays to treatment adjustments or adjunctive therapies among important subpopulations treated
for MDR-TB, e.g. those with HIV co-infection or baseline negative sputum smears. These findings
reinforce the need for expanded global laboratory capacity for high-quality culture, in addition to smear
microscopy and rapid molecular tests. More sensitive indicators of nonresponse, with shorter turnaround
time, would further facilitate early detection and avoid poor outcomes.
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